CryoLife (NYSE:CRY) VP John E. Davis sold 4,373 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $27.00, for a total value of $118,071.00. Following the completion of the transaction, the vice president now owns 55,811 shares in the company, valued at $1,506,897. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
NYSE CRY opened at $26.75 on Monday. The firm has a market cap of $979.91 million, a P/E ratio of 81.06 and a beta of 0.73. The company has a current ratio of 5.07, a quick ratio of 3.72 and a debt-to-equity ratio of 0.77. CryoLife has a fifty-two week low of $16.80 and a fifty-two week high of $27.10.
CryoLife (NYSE:CRY) last released its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.02 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The company had revenue of $61.95 million for the quarter, compared to the consensus estimate of $60.30 million. CryoLife had a positive return on equity of 4.55% and a negative net margin of 1.15%. CryoLife’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.09 earnings per share. equities research analysts anticipate that CryoLife will post 0.3 EPS for the current year.
Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a research report on Friday, May 11th. Canaccord Genuity reiterated a “buy” rating and set a $28.00 target price (up from $25.00) on shares of CryoLife in a research report on Friday, March 9th. Northland Securities reiterated a “buy” rating and set a $23.50 target price on shares of CryoLife in a research report on Thursday, March 8th. Finally, ValuEngine downgraded CryoLife from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $26.63.
A number of large investors have recently bought and sold shares of the business. State of Tennessee Treasury Department raised its holdings in CryoLife by 18.7% during the fourth quarter. State of Tennessee Treasury Department now owns 26,388 shares of the medical equipment provider’s stock valued at $505,000 after acquiring an additional 4,152 shares during the period. New York State Common Retirement Fund raised its holdings in CryoLife by 13.0% during the first quarter. New York State Common Retirement Fund now owns 36,500 shares of the medical equipment provider’s stock valued at $732,000 after acquiring an additional 4,200 shares during the period. Monarch Partners Asset Management LLC raised its holdings in CryoLife by 24.9% during the fourth quarter. Monarch Partners Asset Management LLC now owns 22,730 shares of the medical equipment provider’s stock valued at $435,000 after acquiring an additional 4,530 shares during the period. Principal Financial Group Inc. raised its holdings in CryoLife by 1.9% during the first quarter. Principal Financial Group Inc. now owns 263,759 shares of the medical equipment provider’s stock valued at $5,288,000 after acquiring an additional 5,037 shares during the period. Finally, California Public Employees Retirement System raised its holdings in CryoLife by 6.6% during the third quarter. California Public Employees Retirement System now owns 95,172 shares of the medical equipment provider’s stock valued at $2,160,000 after acquiring an additional 5,872 shares during the period. 67.47% of the stock is currently owned by institutional investors and hedge funds.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for CryoLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife and related companies with MarketBeat.com's FREE daily email newsletter.